Basic aspects of pathophysiology, diagnosis and treatment of patients with pulmonary arterial hypertension associated with human immunodeficiency virus infection: what has been achieved and what remains to be achieved?

Human immunodeficiency virus (HIV) infection is characterized by high morbidity and is a significant threat to human health, increasing global mortality. The number of people living with HIV infection is estimated by the United Nations Joint Program on Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (UNAIDS) to be 39 million (33.1-45.7 million) in 2022. With the introduction of highly effective antiretroviral therapy (cART) into clinical practice and the resulting increase in life expectancy in this cohort of patients, HIV-associated complications have come to the forefront, among which the most severe is pulmonary arterial hypertension (PAH), characterized by a progressive increase in pulmonary vascular resistance and pulmonary artery pressure, leading to the development of right ventricular failure. Subsequently, it became evident that this pathology can occur at all stages of HIV infection and, apparently, has no clear relationship with the degree of immunodeficiency, and is an independent predictor of mortality in patients with LAH-HIV, and therefore requires separate, close attention. This article provides an overview covering the basic pathophysiology, clinical manifestations, diagnosis and treatment of HIV-associated LAH (LAHHIV), emphasizing the challenges encountered at each stage. The review also considers current aspects aimed at studying LAH in patients with HIV, including new experimental drug therapies that take into account the interaction of different regimens with LAH-specific drugs.

1. Oldroyd SH, Manek G, Sankari A, et al. Pulmonary Hypertension. StatPearls. [2023. Accessed January 25, 2024]. https://www.ncbi.nlm.nih.gov/books/NBK482463/

2. Humbert M, Kovacs G, Hoeper MM, et al. ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J 2022;43(38):3618–373. https://doi.org/10.1093/eurheartj/ehac237

3. Butrous G. Human immunodeficiency viruses and their effect on the pulmonary vascular bed. Am J Physiol Lung Cell Mol Physiol. 2021;1;321(6):L1062-L1066. https://doi.org/10.1152/ajplung.00451.2021

4. Palakeel JJ, Ali M, Chaduvula P, et al. An Outlook on the Etiopathogenesis of Pulmonary Hypertension in HIV. Cureus. 2022;14(7):e27390. https://doi.org/10.7759/cureus.27390

5. Hon SM, Alpizar-Rivas RM, Farber HW. Pulmonary Arterial Hypertension in Patients Infected with the Human Immunodeficiency Virus. Cardiol Clin. 2022;40(1):45-54. https://doi.org/10.1016/j.ccl.2021.08.004

6. Wong CM, Bansal G, Pavlickova L, et al. Reactive oxygen species and antioxidants in pulmonary hypertension. Antioxid Redox Signal. 2013;18(14):1789-96. https://doi.org/10.1089/ars.2012.4568

7. Simenauer A, Nozik-Grayck E, Cota-Gomez A. The DNA Damage Response and HIV-Associated Pulmonary Arterial Hypertension. Int J Mol Sci. 2020;21(9):3305. https://doi.org/10.3390/ijms21093305

8. Cicalini S, Almodovar S, Grilli E, Flores S. Pulmonary hypertension and human immunodeficiency virus infection: epidemiology, pathogenesis, and clinical approach. Clin Microbiol Infect. 2011;17(1):25-33. https://doi.org/10.1111/j.1469-0691.2010.03286.x

9. Golpe R, Fernandez-Infante B, Fernandez-Rozas S. Primary pulmonary hypertension associated with human immunodeficiency virus infection. Postgrad Med J. 1998;74(873):400-4. https://doi.org/10.1136/pgmj.74.873.400

10. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest. 2000;118(4):1133-41. https://doi.org/10.1378/chest.118.4.1133

11. Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun. 2005;333(4):1107- 15. https://doi.org/10.1016/j.bbrc.2005.05.198

12. Mirrakhimov AE, Ali AM, Barbaryan A, Prueksaritanond S. Human immunodeficiency virus and pulmonary arterial hypertension. ISRN Cardiol. 2013;2013:903454. https://doi.org/10.1155/2013/903454

13. Suh AJ, Suzuki DI, Gychka SG, et al. gp120 Envelope Glycoproteins of HIV-1 Group M Subtype A and Subtype B Differentially Affect Gene Expression in Human Vascular Endothelial Cells. Int J Mol Sci. 2023;24(4):3536. https://doi.org/10.3390/ijms24043536

14. Avdeev S.N., Barbarash O.L., Bautin A.E., et al. 2020. Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2021;26(12):4683. (In Russ.) https://doi.org/10.15829/1560-4071-2021-4683

15. Peng Y, Dai J, Zhao YY. Egln1Tie2Cre Mice Exhibit Similar Therapeutic Responses to Sildenafil, Ambrisentan, and Treprostinil as Pulmonary Arterial Hypertension (PAH) Patients, Supporting Egln1Tie2Cre Mice as a Useful PAH Model. Int J Mol Sci. 2023;24(3):2391. https://doi.org/10.3390/ijms24032391

16. Rodriguez-Irizarry VJ, Schneider AC, Ahle D, et al. Mice with humanized immune system as novel models to study HIV-associated pulmonary hypertension. Front Immunol. 2022;13:936164. https://doi.org/10.3389/fimmu.2022.936164

17. DeJesus E, Saleh S, Cheng S, et al. Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults. Pulm Circ. 2019;9(2):2045894019848644. https://doi.org/10.1177/2045894019848644

18. Jungmann NA, Lang D, Saleh S, et al. In vitro-in vivo correlation of the drug-drug interaction potential of antiretroviral HIV treatment regimens on CYP1A1 substrate riociguat. Expert Opin Drug Metab Toxicol. 2019;15(11):975-984. https://doi.org/10.1080/17425255.2019.1681968

19. Opravil M, Pechère M, Speich R, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med. 1997;155(3):990-5. https://doi.org/10.1164/ajrccm.155.3.9117037

20. Henriques-Forsythe M, Annangi S, Farber HW. Prevalence and hospital discharge status of human immunodeficiency virus-associated pulmonary arterial hypertension in the United States. Pulm Circ. 2015;5(3):506-12. https://doi.org/10.1086/682222

21. Chazova I.E., Arkhipova O.A., Martynyuk T.V. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry. Therapeutic Archive. 2019;91(1):10–31. https://doi.org/10.26442/00403660.2019.01.000024

22. Reinsch N, Buhr C, Krings P, et al. Competence Network of Heart Failure. Effect of gender and highly active antiretroviral therapy on HIV-related pulmonary arterial hypertension: results of the HIV-HEART Study. HIV Med. 2008;9(7):550-6. https://doi.org/10.1111/j.1468-1293.2008.00602.x

23. Chazova I.E., Martynyuk T.V., Valieva Z.S. et al. Eurasian Guidelines for the diagnosis and treatment of pulmonary hypertension. Eurasian Нeart Journal 2020;1:78-122. (In Russ.) https://doi.org/10.38109/2225-1685-2020-1-78-122

24. Niakara A, Drabo YJ, Kambire Y, et al. Atteintes cardio-vasculaires et infection par le VIH: étude de 79 cas au CHN de Ouagadougou (Burkina Faso) [Cardiovascular diseases and HIV infection: study of 79 cases at the National Hospital of Ouagadougou (Burkina Faso)]. Bull Soc Pathol Exot. 2002;95(1):23-6. (in French). PMID: 12012958

25. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010-9. https://doi.org/10.1161/CIRCULATIONAHA.107.742510

26. Rivera-Lebron BN, Risbano MG. Ambrisentan: a review of its use in pulmonary arterial hypertension. Ther Adv Respir Dis. 2017;11(6):233-244. https://doi.org/10.1177/1753465817696040

27. Channick RN, Delcroix M, Ghofrani HA, et al. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart Fail. 2015;3(1):1-8. https://doi.org/10.1016/j.jchf.2014.07.013

28. Souza R, Delcroix M, Galié N, et al. Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension. Adv Ther. 2022;39(9):4374-4390. https://doi.org/10.1007/s12325-022-02199-x

29. Martynyuk T.V., Nakonechnikov S.N., Chazova I.Y. New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension. Terapevticheskii arkhiv. 2018;4(90):72-80 (in Russ.).

30. Duggan ST, Keam SJ, Burness CB. Selexipag: A Review in Pulmonary Arterial Hypertension. Am J Cardiovasc Drugs. 2017;17(1):73-80. https://doi.org/10.1007/s40256-016-0209-9

31. Isasti G, Moreno T, Pérez I, et al. High prevalence of pulmonary arterial hypertension in a cohort of asymptomatic HIV-infected patients. AIDS Res Hum Retroviruses. 2013;29(2):231-4. https://doi.org/10.1089/AID.2012.0166

32. Isasti G, Pérez I, Moreno T, et al. Echocardiographic abnormalities and associated factors in a cohort of asymptomatic HIV-infected patients. AIDS Res Hum Retroviruses. 2013 Jan;29(1):20-4. https://doi.org/10.1089/AID.2012.0096

33. Ilyin N.V., Ivanov K.I., Martynyuk T.V. New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag. Cardiovascular Therapy and Prevention. 2019;18(6):80–87. (In Russ.). https://doi.org/10.15829/1728-8800-2019-6-80-87

34. Kumar A, Mahajan A, Salazar EA et al. Impact of human immunodeficiency virus on pulmonary vascular disease. Glob Cardiol Sci Pract. https://doi.org/10.21542/gcsp.2021.12

35. Krowka MJ, Miller DP, Barst RJ, et al. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest. 2012;141(4):906-915. https://doi.org/10.1378/chest.11-0160

36. Chazova I.E., Martynyuk T.V. Pulmonary hypertension. - Moscow. Praktika. 2015; 928p. (In Russ.).

37. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. European Respiratory Journal. 2008;31(2):407-15. https://doi.org/10.1183/09031936.00078207